Once cleaved by caspases, the Lyn tyrosine kinase (LynDN) is relocalized from the plasma membrane to the cytoplasm of apoptotic cells, but the function of such a cleavage is incompletely understood. We evaluated the effect of LynDN overexpression on imatinib sensitivity of the chronic myelogenous leukemia (CML) cell line K562. Therefore, we generated stable cells that express plasmids encoding LynDN or its catalytically inactive counterpart LynDNKD. We established that Lyn is cleaved in imatinib-treated parental K562 cells in a caspase-dependent manner. Lyn cleavage also occurred following BCR-ABL silencing by specific short hairpin RNA (sh-RNA). Imatinib-induced apoptosis was abrogated in Lyn DN-overexpressing cells, but not in cells overexpressing its inactive counterpart. Conversely, the overexpression of LynDN failed to affect the differentiation of K562 cells. Importantly, the protective effect of LynDN was suppressed by two inhibitors of Lyn activity. LynDN also inhibits imatinib-mediated caspase-3 activation in the small proportion of nilotinib-resistant K562 cells overexpressing Lyn that can engage an apoptotic program upon imatinib stimulation. Finally, Lyn knockdown by sh-RNA altered neither imatinib-mediated apoptosis nor differentiation. Taken together, our data show that the caspase-cleaved form of Lyn exerts a negative feedback on imatinib-mediated CML cell apoptosis that is entirely dependent on its kinase activity and likely on the BCR-ABL pathway.
Introduction
The Src family of tyrosine kinases consists of nine known members that play important roles in a variety of cellular functions, such as growth, proliferation, differentiation and regulation of apoptosis. 1, 2 All Src kinases share a common structural organization that includes (i) an N-terminal region that contains the myristoylation and/or palmitoylation sites required for their membrane localization, (ii) a region with highest diversity called the SH4 domain followed by (iii) SH3 and SH2 domains involved in protein-protein interactions and (iv) a catalytic domain essential for their activity. The function of Lyn has been widely studied in hematopoietic cells, including B cells, mast cells and myeloid cells. Noticeably, mice deficient in Lyn have a reduced number of peripheral B cells and defective responses following B-cell receptor engagement. [3] [4] [5] Later on they exhibit splenomegaly, a lupus-like disease, 6 and an elevated level of myeloid precursors. 7 It has also been reported that Lyn exerts previously unknown negative functions in the regulation of both erythropoiesis [8] [9] [10] and megakaryocytopoiesis. 11, 12 Chronic myelogenous leukemia (CML) is a myeloproliferative syndrome linked to the t(9;22) (q34;q11) translocation responsible for the expression of p210 BCR-ABL, a fusion protein endowed with constitutive tyrosine kinase activity. 13, 14 BCR-ABL triggers several survival pathways, including STAT5/Bcl-xL, Erk-1/2, PI3K/Akt, Src, nuclear factor-kB and Jak2, that collectively provide proliferative advantages and resistance to apoptosis. 11, 12, 15 Src kinases also regulate BCR-ABL function through the phosphorylation of a tyrosine residue located in the SH2/SH3 domains or in the BCR sequence. 16, 17 Imatinib binds to BCR-ABL and selectively induces growth arrest and apoptosis of BCR-ABL-expressing leukemia cells. 18 Although imatinib is very effective in patients in the chronic phase of CML, 19 it is less efficacious during accelerated phase and blast crisis, [20] [21] [22] and therefore resistance is a common feature of patients with accelerated phase or blast crisis. 23 Interestingly, among other types of resistance, overexpression of Lyn has also been reported. 24 Lyn and Fyn are cleaved in their unique regions by caspases in T and B cells undergoing apoptosis. [25] [26] [27] [28] Regarding Lyn, cleavage is initiated by caspase-3 and occurs after aspartate 18. This cleavage eliminates the short N-terminal sequence that contains the acylation sites required for Lyn plasma membrane insertion. As a consequence, the caspase-cleaved form of Lyn is relocated from the plasma membrane to the cytosol of cells undergoing apoptosis. 28 In this study, the role of the caspase-cleaved form of Lyn either in an active (LynDN) or in the inactive (LynDNKD) configuration was investigated. In contrast to its catalytically inactive counterpart, the caspase-cleaved form of Lyn efficiently protected K562 cells against imatinib-induced apoptosis, without affecting their differentiation. The requirement of the kinase activity of Lyn in this protection was shown using an inactive form of Lyn and two Src kinase inhibitors, PP2 and SU6656, which resensitized LynDN K562 cells to imatinib-mediated apoptosis. Finally, LynDN inhibits imatinib-mediated apoptosis in the small fraction of nilotinibresistant (Nilo-R) K562 cells overexpressing Lyn that engages an apoptotic program upon imatinib stimulation. Taken together, our data indicate that Lyn exerts a negative control on CML cell apoptosis that is entirely dependent on its kinase activity.
Reverse transcription PCR analysis
Total RNAs were isolated using Trizol Reagent (Invitrogen, Cergy Pontoise, France) and treated for reverse transcription PCR analysis as described earlier. 29 
Western blot assays
Western blot analysis has been described elsewhere. 29 
Subcellular localization of Lyn
Preparation of cytoplasmic and microsomal fractions has been described earlier. 29 
Caspase activity measurement
After stimulation, cells were lysed for 30 min at 4 1C in lysis buffer and lysates were cleared at 10 000 g for 15 min at 4 1C. Each assay (in triplicate) was performed with 50 mg of protein prepared from control or stimulated cells. Briefly, cellular extracts were incubated in a 96-well plate, with 0.2 mM of Ac-DEVD-AMC (7-amino-4methylcoumarin) as substrate for various times at 37 1C as described earlier. 31 
Cell viability analysis (XTT)
Cell viability measurements have been described elsewhere. 31 Benzidine staining and phase contrast microscopy Cell hemoglobinization was analyzed by benzidine staining as described earlier. 31 Then, 100 ml of cells (10 6 per ml) was mixed with 10 ml benzidine dihydrochloride reagent (Sigma). Erythroid differentiation was visualized following benzidine staining using standard phase optics (Zeiss, Oberkochen, Germany) and cells were counted by three independent investigators.
Flow cytometry
After stimulation, cells were washed with ice-cold phosphatebuffered saline, fixed and permeabilized with Cytofix/Cytoperm solution. Cells were incubated for 30 min with anti-activecaspase 3-fluorescein isothiocyanate monoclonal antibody, washed and resuspended in Perm/Wash solution. In some experiments, cells were incubated for 48 h with or without zVAD-fmk and stained with the annexin-V-fluos staining kit (Roche, Meylan, France). Fluorescence was measured by using the FL1 and FL2 channels of a fluorescence-activated cell sorting apparatus (FACScan; Becton Dickinson, Cowley, UK). Assessment of differentiation of K562 cells and conditions for the cell cycle analysis has been described earlier. 11, 31, 32 Lyn and caspase-9 sh-RNA-expressing K562 cells Short hairpin RNA (sh-RNA)-expressing plasmids were constructed targeting a specific region of human Lyn (5 0 -AGTGA AGCAAATCAGAAAC-3 0 ) or caspase-9 (5 0 -CAGATGCCT6GGT TGCTTTA-3 0 ). The oligonucleotides purchased from Eurogentec SA (Seraing, Belgium) were annealed and cloned into the pTER vector using the BglII and HindIII restriction sites. 29 This results in a tetracycline (tet)-inducible sh-RNA expression system when stably cotransfected into K562 (tet-on) cells with the pcDNA6/ TR vector (Invitrogen Ltd, Paisley, UK).
Results

Lyn is cleaved in imatinib-treated K562 CML cells
Lyn extracted from K562 cells appears as two molecular species migrating on SDS-polyacrylamide gel electrophoresis at 56 and 53 kDa corresponding to the known isoforms described for this Src kinase (Supplementary Figure S1A) . In imatinib-treated K562 cells, Lyn is processed into its characteristic cleavage product migrating at 51 kDa. 27, 28 This form shows maximal accumulation after 48 h, when the optimal induction of cell death occurs. 29 The cleavage product at 54 kDa, which arises from the 56 kDa isoform, was clearly detectable when the concentration of acrylamide in the gel was reduced (Supplementary Figure  S1B) . Lyn cleavage correlated with the appearance of active caspase-3 and the cleavage of poly (ADP-ribose) polymerase, and it was prevented by z-VAD-fmk, confirming the role of caspases in Lyn cleavage (Supplementary Figure S1A) . Interestingly, tet-mediated knockdown of BCR-ABL also triggered Lyn cleavage (Supplementary Figure S2A) . To analyze further the role of caspases in Lyn cleavage, we used K562 cells stably expressing tet-inducible caspase sh-RNA. In the absence of tet, imatinib induced the cleavage of Lyn into its characteristic fragments, which were not detected in untreated cells (Supplementary Figure S2B and C). Interestingly, caspase-3 or -9 knockdown prevented Lyn cleavage, in contrast to GFP-shRNA. To investigate the function of the Lyn molecule cleaved by caspases, we generated two K562 cell lines expressing either LynDN or its catalytically inactive counterpart, LynDNKD. Supplementary Figure S1B illustrates that (i) both clones exhibit similar levels of p53/56Lyn and BCR-ABL proteins, (ii) dephosphorylation of BCR-ABL by imatinib is equivalent in the three clones and (iii) ectopic expression of LynDN proteins is similar in the different clones.
LynDN increases K562 cell viability and protects them from imatinib-mediated growth arrest
Imatinib induced a drastic loss of cell metabolism in parental and K562 cells expressing LynDNKD, whereas LynDN-expressing K562 cells were protected from the imatinib effect ( Figure 1a and Supplementary Figure S3A ). The protective effect of LynDN was less pronounced after 72 h of imatinib treatment, when cells die mainly from caspase-independent death. An increase in cells in the G0/G1 phase of the cell cycle, together with a marked decrease in the fraction with fully replicated DNA (G2/M), occurred within 48 h of imatinib addition to parental K562 cells (Figure 1b) . At later time points, an increasing number of cells accumulated in the sub-G1 phase of the cell cycle in the presence of imatinib. This was also the case for K562 cells expressing LynDNKD. No modification was detected in K562-LynDN cells after 48 h of incubation with imatinib ( Figure 1b) .
Overexpression of LynDN fully protects K562 cells from imatinib-induced apoptosis
Next, we investigated the effect of expression of LynDN either in its active or in its inactive form on imatinib-mediated apoptosis. 
SU6656 and PP2 impair the protective effect of LynDN on imatinib-mediated apoptosis
If LynDN activity is a prerequisite for its protective effect, Src kinase inhibitors should resensitize LynDN-expressing cells to imatinib-induced apoptosis. Accordingly, SU6656 or PP2 alleviated LynDN protection in K562-LynDN cells (Figure 3a) . This resensitization was confirmed using cell metabolism assays (Figure 3b) . Moreover, the protective effect of LynDN on imatinib-mediated apoptosis is specific, as resveratrol, a known inducer of apoptosis in K562 cells, 33 triggered caspase-3 activation and loss of cell viability in parental, LynDN-and LynDNKD-expressing cells as well (Figure 3a and b) .
LynDN overexpression does not alter erythroid differentiation of K562 cells
In addition to inducing K562 cell death, imatinib triggers their erythroid differentiation. 29 Benzidine staining of K562 cells revealed an increase in the number of cells engaged in erythroid differentiation upon imatinib treatment, but no difference was observed in parental versus K562 cells expressing LynDN or LynDNKD (Supplementary Figure S4A) . Moreover, in the three series of cells, the number of benzidine-positive cells reached 50% versus only 3-5% in untreated cells (Supplementary Figure S4B) . Finally, the fact that LynDN did not affect imatinib-mediated erythroid differentiation was further substan- Figure S4C) and reverse transcription PCR amplification of several specific erythroid markers (Supplementary Figure S4D ) in cells treated for 48 h with imatinib.
Effect of overexpression of LynDN in Nilo-R K562 cells overexpressing Lyn
We recently generated a Nilo-R K562 cell line that overexpresses Lyn as a mechanism of resistance 30 ( Figure 4a ). In contrast to parental K562 cells, very few Lyn cleavage and no caspase-3 activation were detected in Nilo-R cells in response to imatinib showing that they are also cross-resistant to imatinib (Supplementary Figure S5A) . Interestingly, the overexpression of Lyn was mainly observed in the cytoplasmic fraction of Nilo-R cells (Figure 4b ). Next we cotransfected various Lyn constructs in parental or Nilo-R cells together with a green fluorescent protein vector and investigated their effect on imatinib-mediated caspase-3 activity using fluorescence-activated cell sorting analysis. As shown in Figure 4c , transfection of a catalytically inactive form of Lyn or LynDN in parental K562 cells increased caspase-3 activity in both the absence and the presence of imatinib, suggesting that they do exert a dominant-negative effect on apoptosis. Importantly, the catalytically active forms of Lyn (LynWT or LynDN) efficiently inhibited imatinib-mediated 
Lyn sh-RNA affects neither imatinib-mediated cell death nor erythroid differentiation
We also generated a K562 cell line stably expressing a tetinducible sh-RNAi directed against Lyn. Treatment of this cell line with tet resulted in a time-dependent inhibition of Lyn expression that culminated at day 7. At this time, Lyn expression was inhibited by more than 90% (Supplementary Figure S6A) . To investigate the effect of Lyn silencing on imatinib-mediated cell death, parental and sh-RNA-expressing cells were first treated for 5 days with tet before the addition of 1 mM imatinib for the last 2 days. Supplementary Figure S6B -D showed that Lyn knockdown in tet-treated cells altered neither imatinibmediated loss of cell viability nor caspase-3 activation. Finally, Lyn silencing failed to affect imatinib-induced erythroid differentiation as assessed by benzidine staining of differentiated cells or caspase-3 and glycophorin A staining by flow cytometry (Supplementary Figures S6E and F) .
Discussion
We have identified earlier a new mechanism of Lyn kinase regulation that implies its cleavage by caspases in B-cell lines undergoing apoptosis.
27,28 Interestingly, we have also shown that the expression of the caspase-cleaved form of Lyn (LynDN) can protect B-cell lines from B-cell receptor-mediated apoptosis. 28 Thus, it was of importance to determine whether the cleavage of Lyn might also occur in a different cellular context, that is in CML cells treated with imatinib, and if so, whether the overexpression of the cleaved form of Lyn can protect CML cells from apoptosis induced by this BCR-ABL inhibitor. This is particularly important as Lyn overexpression has been identified as a major cause of resistance to imatinib in some CML cell lines and patients. [34] [35] [36] Moreover, as the caspase-cleaved form of Lyn exhibits increased tyrosine kinase activity compared with its normal counterpart, 27 we determined the importance of Lyn activity in these processes. We established that Lyn is cleaved in a caspase-dependent manner in imatinib-treated K562 cells and also when BCR-ABL was knocked down by specific sh-RNA. We also showed that imatinib-induced cell death is severely inhibited in LynDN-overexpressing K562 cells. Interestingly, the protective effect of LynDN is specific for imatinib-mediated apoptosis, as resveratrol, a known inducer of apoptosis in K562 cells, 33 triggered caspase-3 activation and loss of cell viability in LynDN-overexpressing cells. We and others have shown earlier that resveratrol triggered hematopoietic cell death by both caspase-dependent and -independent mechanisms, 37,38 but independently of BCR-ABL. 31 LynDN effect was restricted to protection against apoptosis, as it did not impair the caspaseindependent imatinib contribution on cell death. The fact that LynDN protects K562 cells from imatinib-mediated apoptosis by inhibiting caspases was confirmed by the absence of any further protection by the pancaspase inhibitor z-VAD-fmk in LynDNoverexpressing K562 cells. This is in contrast to the situation observed in parental and LynDNKD K562 cells in which z-VADfmk elicited a clear protection.
Although complex in nature, the antileukemic effect of imatinib is thought to rely on different or overlapping events, including cell cycle arrest, cell death induction by either caspase-dependent or -independent mechanisms and erythroid differentiation. 29 However, erythroid differentiation proceeded in K562 cells expressing LynDN or LynDNKD as well, indicating that the cleaved form of Lyn did not interfere with differentiation. This observation is in agreement with the fact that imatinib-mediated apoptosis and erythroid differentiation are independent events. 29 As K562 cells can also undergo megakaryocytic differentiation when stimulated with the phorbol ester PMA, 31, 32, 39 we also investigated whether LynDN expression may affect this differentiation program. LynDN failed to affect the megakaryocytic differentiation of K562 cells too (Supplementary Figure S7) .
Lyn plays a significant role in BCR-ABL signaling, and Lyn overexpression and activity are associated with some modes of imatinib resistance in CML cell lines and CML patients. 34 , 35 We reported herein that Lyn knockdown altered neither imatinibmediated apoptosis nor differentiation. At the first glance, the lack of effect of Lyn silencing on cell death may appear surprising, as Lyn is important for K562 cell survival. However, our findings are in agreement with a recent study showing that Lyn knockdown by si-RNA does not trigger apoptosis in imatinib-sensitive K562 cells, whereas it does so in imatinibresistant K562 cells overexpressing Lyn. 40 The importance of LynDN kinase activity was confirmed by the fact that the protective effect of LynDN on imatinib-induced apoptosis was suppressed by both SU6656 and PP2, two Src kinase inhibitors, and by the observation that expression of the kinase-dead form of LynDN (LynDNKD) failed to provide protection against imatinib-induced apoptosis. Thus, one could hypothesize that LynDN inhibits one or several events involved in the induction of apoptosis by imatinib. As the effect of LynDN occurs upstream of caspase activation and as LynDN efficiently protects CML cells from mitochondria-mediated apoptosis, it is tempting to speculate that LynDN may interfere with the function of proapoptotic Bcl-2 family members, therefore impairing their action on mitochondria. In agreement with this hypothesis, we have reported earlier that imatinib-induced apoptosis is integrated at the mitochondrial level and is accompanied by caspase-3 and -9 activation. 11 Inhibition of the p42/44 MAPK pathway by imatinib abolished Bim-EL phosphorylation on serine 69, impairing its degradation by the proteasome. 41 The subsequent stabilization of Bim is crucial for the induction of apoptosis in CML cells and also in other cell types. [41] [42] [43] In line with these findings, Kuroda et al. 43 recently showed that Bim and Bad are major players of imatinibmediated cell killing in BCR-ABL-positive leukemic cells. Therefore, one attractive hypothesis to explain the inhibitory effect of LynDN on apoptosis would be that once relocated into the cytoplasm consecutively to its cleavage by caspases, LynDN phosphorylates on tyrosine residues, some components of the mitochondrial apoptotic machinery, the most likely candidate being Bim. Further studies are needed to decipher the mechanisms by which LynDN exerts its antiapoptotic effect.
One of the primary causes of resistance to chemotherapy in leukemia is insensitivity to cell death because of increased expression of survival pathways. Src kinases, including Lyn, are important for BCR-ABL signaling and for some modes of resistance to imatinib in refractory CML cell lines or patients. 24, [34] [35] [36] It is noteworthy that the overexpression of Lyn in Nilo-R K562 cells is detected essentially in the cytoplasmic fraction. Therefore, it is tempting to speculate that this increase in cytoplasmic Lyn might contribute to resistance to tyrosine kinase inhibitors, including imatinib and nilotinib. The notion that a cytoplasmic and active form of Lyn released by caspases might be involved in defective apoptosis in CML and other hematopoietic malignancies is novel and may have an important impact on our understanding of leukemogenesis and possibly on the treatment of leukemia.
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